Dose-Ranging Study of AVI-4658 to Induce Dystrophin Expression in Selected Duchenne Muscular Dystrophy (DMD) Patients
Completed
British Medical Research Council
Phase 1/Phase 2
2009-01-01
The specific aim of this Phase I/II study is to assess the safety of intravenous administered
Morpholino oligomer directed against exon 51 (AVI-4658 PMO).
Dose-Ranging Study of AVI-4658 to Induce Dystrophin Expression in Selected Duchenne Muscular Dystrophy (DMD) Patients
Completed
Sarepta Therapeutics
Phase 1/Phase 2
2009-01-01
The specific aim of this Phase I/II study is to assess the safety of intravenous administered
Morpholino oligomer directed against exon 51 (AVI-4658 PMO).
Dose-Ranging Study of AVI-4658 to Induce Dystrophin Expression in Selected Duchenne Muscular Dystrophy (DMD) Patients
Completed
Sarepta Therapeutics, Inc.
Phase 1/Phase 2
2009-01-01
The specific aim of this Phase I/II study is to assess the safety of intravenous administered
Morpholino oligomer directed against exon 51 (AVI-4658 PMO).
Efficacy Study of AVI-4658 to Induce Dystrophin Expression in Selected Duchenne Muscular Dystrophy Patients
Completed
Sarepta Therapeutics
Phase 2
2011-07-01
This study is designed to assess the efficacy, safety, tolerability, and pharmacokinetics
(PK) of AVI-4658 (eteplirsen) in both 50.0 mg/kg and 30.0 mg/kg doses administered over 24
weeks in subjects diagnosed with Duchenne muscular dystrophy (DMD).
Efficacy Study of AVI-4658 to Induce Dystrophin Expression in Selected Duchenne Muscular Dystrophy Patients
Completed
Sarepta Therapeutics, Inc.
Phase 2
2011-07-01
This study is designed to assess the efficacy, safety, tolerability, and pharmacokinetics
(PK) of AVI-4658 (eteplirsen) in both 50.0 mg/kg and 30.0 mg/kg doses administered over 24
weeks in subjects diagnosed with Duchenne muscular dystrophy (DMD).
Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors.
Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data.
The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free.
thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user.
Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.
Alerts Available With Subscription
Alerts are available for users with active subscriptions.